Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23403836 | 0.84 | JAK2 (0.34) | JAK2BTK | |
| SCHEMBL18487465 | 0.81 | BUB1 (0.38) | BUB1PRMT5WDR77USP30AAK1 | |
| SCHEMBL16336927 | 0.79 | BUB1 (0.37) | BUB1PRMT5WDR77USP30AAK1 | |
| SCHEMBL17879718 | 0.78 | JAK2 (0.37) | JAK2BTK | |
| SCHEMBL31056884 | 0.77 | BUB1 (0.35) | BUB1PRMT5WDR77USP30AAK1 | |
| SCHEMBL29326532 | 0.77 | BUB1 (0.35) | BUB1PRMT5WDR77USP30AAK1 | |
| SCHEMBL21652803 | 0.77 | BUB1 (0.39) | BUB1BRD4 | |
| SCHEMBL30951333 | 0.76 | BUB1 (0.36) | BUB1PRMT5WDR77USP30AAK1 | |
| SCHEMBL17179245 | 0.76 | L3MBTL1 (0.37) | BUB1PRMT5WDR77USP30JAK2 | |
| SCHEMBL29361265 | 0.76 | L3MBTL1 (0.37) | BUB1PRMT5WDR77USP30JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522600-B2 | Crystal form and salt form of bromine domain protein inhibitor and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-115716827-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-4092027-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-112424200-B | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114929703-A | Crystal form and salt form of bromodomain domain protein inhibitor and preparation method thereof | 正大天晴药业集团股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2021143922-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | 正大天晴药业集团股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| CN-112424200-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020020288-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | BRD1, BRD4, BRD2 | BUB1 1103/4885PRMT5 307/4885WDR77 530/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | BUB1 374/4885PRMT5 1093/4885WDR77 356/4885 |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | BET1, BRD7, BRWD1 | BUB1 1450/4885PRMT5 1507/4885WDR77 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.